GlobeNewswire Inc | Nov 12, 2021 07:00AM EST

November 12, 2021

TORONTO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2021.

Third Quarter 2021 Summary & Recent Highlights:

-- Total revenue of $24.6 million, up $3.9 million, or 19%, year-over-year. U.S. revenue of $13.0 million, up $5.2 million, or 67%, year-over-year.Total subscription and system revenue of $20.7 million, up $3.7 million, or 22% year-over-year. -- Gross margin of 70.5%, up 5.2% year-over-year. -- GAAP operating loss of $5.4 million, up $0.1 million, or 2%, year-over-year. -- GAAP net loss attributable to stockholders of $9.8 million, up $2.6 million, or 35%, year-over-year. -- Adjusted EBITDA loss of $3.5 million, up $2.2 million, or 155%, year-over-year. -- The Company received a Health Canada medical device license to market the Venus Fiore Feminine Health System in Canada in July and FDA 510(k) clearance to market the Venus Freedom device in the United States in October. -- On October 12, 2021, the Company announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021.

Management Commentary:

Third quarter revenue results reflect strong demand from customers, particularly in the United States, despite the challenging operating environment, said Domenic Serafino, Chief Executive Officer of Venus Concept. Strong execution of our focused commercial strategy in the United States drove revenue growth of 67% year-over-year, which offset a 10% year-over year decrease in international revenue. International revenue results were impacted by our inability to fulfill demand for certain of our products due to the global supply disruptions related to COVID-19 which resulted in a backlog for customer purchase orders received of $2.4 million as of the end of the third quarter, of which we have fulfilled $1.4 million in the first half of the fourth quarter. We continue to actively work with our suppliers and third-party manufacturers to mitigate supply issues and intend to fulfill the remaining customer purchase order backlog in the fourth quarter of fiscal year 2021 and the first quarter of fiscal year 2022.

Mr. Serafino continued: Based on our current assessment and strong pipeline activity, we believe that we will continue to see an improvement in capital equipment demand in the aesthetics and hair restoration markets as we move through 2021. We remain confident in our ability to deliver strong growth and we have tightened our expectations for revenue growth to 33% to 37% year-over-year in fiscal year 2021. We continue to expect to drive strong operating leverage in 2021, as well. Importantly, our longer-term outlook is compelling as we continue to make progress in the area of product development; specifically, our efforts to develop AIme, the next generation robotic technology for medical aesthetic applications.

Third Quarter and First Nine Months of 2021 Revenue by Region and by Product Type:

Three Months Nine Months Ended September30, Ended September30, 2021 2020 2021 2020 (dollars in thousands) (dollars in thousands) Revenues by region:United States $ 12,962 $ 7,784 $ 37,025 $ 22,339 International 11,601 12,896 35,963 29,845 Total revenue $ 24,563 $ 20,680 $ 72,988 $ 52,184

Three Months Nine Months Ended September30, Ended September30, 2021 2020 2021 2020 (dollars in thousands) (dollars in thousands) Revenues by product: Subscription?Systems $ 12,634 $ 9,431 $ 33,958 $ 23,709 Products?Systems 8,022 7,503 26,526 17,758 Products?Other ^(1) 2,961 2,631 9,330 7,136 Services^ (2) 946 1,115 3,174 3,581 Total revenue $ 24,563 $ 20,680 $ 72,988 $ 52,184

(1)Products-Other include ARTAS procedure kits and other consumables.(2)Services include VeroGrafters technician services and extended warranty sales.

Third Quarter 2021 Financial Results:

Three Months Ended September30, 2021 2020 Change (in thousands, except $ %ofTotal $ %ofTotal $ % percentages)Revenues: Subscription?Systems $ 12, 51.4 $ 9,431 45.6 $ 3,204 34.0 634Products?Systems 8,022 32.7 7,503 36.3 519 6.9 Products?Other 2,961 12.1 2,631 12.7 331 12.6 Services 946 3.8 1,115 5.4 (169 ) (15.2 )Total $ 24,563 100.0 $ 20,680 100.0 $ 3,883 18.8

Total revenue for the third quarter of 2021 increased $3.9 million, or 19%, to $24.6 million, compared to the third quarter of 2020. The increase in total revenue, by region, was driven by a 67% increase year-over-year in United States revenue, offset partially by a 10% year-over-year decrease in international revenue. The increase in total revenue, by product category, was driven by a 34% increase in lease revenue, a 7% increase in systems revenue and a 13% increase in products revenue, offset partially by a 15% decrease in services revenue. The percentage of total systems revenue derived from our subscription model was approximately 61% this quarter, compared to approximately 56% for the third quarter of 2020.

Gross profit for the third quarter of 2021 increased $3.8 million, or 28%, to $17.3 million compared to the third quarter of 2020. Gross margin was 70.5%, compared to 65.3% of revenue for the third quarter of 2020. The increase in gross margin was primarily driven by higher sales of Venus consumables and improved revenue mix of system sales sold under our subscription program, primarily tracing to Venus Bliss, and the discontinuation of our 2two5 advertising agency services.

Operating expenses for the third quarter of 2021 increased $3.9 million, or 21%, to $22.7 million compared to the third quarter of 2020. The increase in total operating expenses was driven by an increase of $3.1 million, or 55%, in sales and marketing expenses, an increase of $0.7 million, or 6%, in general and administrative expenses and an increase of $0.1 million, or 4%, in R&D expenses.

Operating loss for the third quarter of 2021 increased $0.1 million, or 2%, year-over-year to $5.4 million.

Net loss attributable to stockholders for the third quarter of 2021 increased $2.6 million, or 35% year-over-year, to $9.8 million, or $0.18 per share. Adjusted EBITDA loss for the third quarter of 2021 increased $2.2 million, or 156% year-over-year, to $3.5 million.

First Nine Months of 2021 Financial Results:

Nine Months Ended September30, 2021 2020 Change (in thousands, except $ %ofTotal $ %ofTotal $ % percentages)Revenues: Subscription?Systems $ 33,958 46.5 $ 23,709 45.4 $ 10,249 43.2 Products?Systems 26,526 36.3 17,758 34.0 8,768 49.4 Products?Other 9,330 12.8 7,136 13.7 2,195 30.8 Services 3,174 4.3 3,581 6.9 (407 ) (11.4 )Total $ 72,988 100.0 $ 52,184 100.0 $ 20,804 39.9

Total revenue for the nine months ended September 30, 2021, increased $20.8 million, or 40%, to $73.0 million. The increase in total revenue, by region, was driven by a 66% increase in United States revenue and a 20% increase in international revenue. The increase in total revenue, by product category, was driven by a 43% increase in lease revenue, a 49% increase in systems revenue and a 31% increase in products revenue, offset partially by a 11% decrease in services revenue. The percentage of total systems revenue derived from our subscription model was approximately 56%, compared to approximately 57% for the nine months ended September 30, 2020.

Net loss attributable to stockholders for the nine months ended September 30, 2021 decreased $51.9 million, or 74%, to $18.7 million, or $0.35 per share. Adjusted EBITDA loss for the nine months ended September 30, 2021 decreased $9.7 million, or 55%, to $8.1 million.

Updated Fiscal Year 2021 Revenue Guidance:

The Company now expects total revenue for the twelve months ending December 31, 2021 in the range of $104.0 million to $107.0 million, representing an increase of approximately 33% to 37%, year-over-year, compared to total revenue of $78.0 million for the twelve months ended December 31, 2020. This compares to the Companys prior guidance range of $102.0 million to $107.0 million.

Conference Call Details:

Management will host a conference call at 8:00 a.m. Eastern Time on November 12, 2021 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13723892. A live webcast of the call will also be provided on the investor relations section of the Companys website at ir.venusconcept.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13723892. The webcast will be archived at ir.venusconcept.com.

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 18 direct markets. Venus Concept focuses its product sales strategy on a subscription-based business model in North America and in its well-established direct global markets. Venus Concepts product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Freedom, Venus Viva, Venus Freeze Plus, Venus Glow, Venus Bliss, Venus Epileve and Venus Viva MD. Venus Concepts hair restoration systems include NeoGraft, an automated hair restoration system that facilitates the harvesting of follicles during a FUE process and the ARTAS and ARTAS iX Robotic Hair Restoration systems, which harvest follicular units directly from the scalp and create recipient implant sites using proprietary algorithms. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, and Aperture Venture Partners.

Cautionary Statement Regarding Forward-Looking Statements

This communication containscontains forward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended and Section21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as anticipates, believes, plans, expects, projects, future, intends, may, should, could, estimates, predicts, potential, continue, guidance, and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, statements aboutour financial performance; the growth in demand for our systems and other products; andgeneral economic conditions, including the global economic impact of COVID-19, and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and managements beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part II Item 1ARisk Factors in our Quarterly Reports on Form 10-Q and Part I Item 1ARisk Factors in our Annual Report on Form10-K for the fiscal year ended December 31, 2020. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.

Venus Concept Inc.Condensed Consolidated Balance Sheets(In thousands of U.S. dollars, except share and per share data)

September30, December 2021 31, 2020ASSETS CURRENT ASSETS: Cash and cash equivalents $ 15,781 $ 34,297 Restricted cash 83 83 Accounts receivable, net of allowance of$11,459 and $18,490 as of September 30, 2021, 47,792 52,764 and December 31, 2020Inventories 21,005 17,759 Prepaid expenses 2,395 2,240 Advances to suppliers 2,728 2,587 Other current assets 4,756 5,674 Total current assets 94,540 115,404 LONG-TERM ASSETS: Long-term receivables 23,243 21,148 Deferred tax assets 785 884 Severance pay funds 742 685 Property and equipment, net 2,575 3,539 Intangible assets 16,268 18,865 Total long-term assets 43,613 45,121 TOTAL ASSETS $ 138,153 $ 160,525 LIABILITIES AND STOCKHOLDERS? EQUITY CURRENT LIABILITIES: Trade payables $ 4,749 $ 6,322 Accrued expenses and other current liabilities 17,180 20,253 Taxes payable 2,149 1,132 Unearned interest income 2,565 1,950 Warranty accrual 1,173 1,106 Deferred revenues 420 1,752 Current portion of government assistance loans 950 ? Total current liabilities 29,186 32,515 LONG-TERM LIABILITIES: Long-term debt 76,857 75,491 Government assistance loans ? 4,110 Taxes payable 478 478 Accrued severance pay 852 755 Deferred tax liabilities 45 811 Unearned interest income 1,291 1,778 Warranty accrual 471 533 Other long-term liabilities 202 293 Total long-term liabilities 80,196 84,249 TOTAL LIABILITIES 109,382 116,764 Commitments and Contingencies (Note 8) STOCKHOLDERS? EQUITY (Note 1): Common Stock, $0.0001 par value: 300,000,000shares authorized as of September 30, 2021 andDecember 31, 2020; 54,157,969 and 53,551,126 26 26 issued and outstanding as of September 30,2021 and December 31, 2020, respectivelyAdditional paid-in capital (Note 1) 204,094 201,598 Accumulated deficit (176,072 ) (157,392 )TOTAL STOCKHOLDERS? EQUITY 28,048 44,232 Non-controlling interests 723 (471 ) 28,771 43,761 TOTAL LIABILITIES AND STOCKHOLDERS? EQUITY $ 138,153 $ 160,525

Venus Concept Inc.Condensed Consolidated Statements of Operations(In thousands of U.S. dollars, except per share data)

Three Months Nine Months Ended September30, Ended September30, 2021 2020 2021 2020 Revenue Leases $ 12,634 $ 9,431 $ 33,958 $ 23,709 Products and services 11,929 11,249 39,030 28,475 24,563 20,680 72,988 52,184 Cost of goods sold Leases 2,938 2,303 7,444 5,296 Products and services 4,319 4,874 14,287 12,208 7,257 7,177 21,731 17,504 Gross profit 17,306 13,503 51,257 34,680 Operating expenses: Selling and marketing 8,775 5,657 26,743 18,813 General and 11,990 11,291 31,983 40,057 administrativeResearch and development 1,930 1,849 6,005 6,043 Goodwill impairment ? ? ? 27,450 Gain on forgiveness ofgovernment assistance ? ? (2,775 ) ? loansTotal operating expenses 22,695 18,797 61,956 92,363 Loss from operations (5,389 ) (5,294 ) (10,699 ) (57,683 )Other expenses: Foreign exchange loss 1,645 1,096 2,489 4,209 Finance expenses 1,000 1,897 4,046 6,522 Loss on disposal of 188 - 188 385 subsidiariesLoss before income taxes (8,222 ) (8,287 ) (17,422 ) (68,799 )Income tax expense 616 (966 ) 609 (1,010 )(benefit)Net loss (8,838 ) (7,321 ) (18,031 ) (67,789 )Deemed dividend - - - (3,564 )Loss attributable tostockholders of the (9,798 ) (7,243 ) (18,680 ) (70,585 )CompanyIncome (loss)attributable to 960 (78 ) 649 (768 )non-controlling interest Net loss per share: Basic $ (0.18 ) $ (0.18 ) $ (0.35 ) $ (2.04 )Diluted $ (0.18 ) $ (0.18 ) $ (0.35 ) $ (2.04 )Weighted-average numberof shares used in per share calculation:Basic 54,145 40,466 53,994 34,553 Diluted 54,145 40,466 53,994 34,553

Use of Non-GAAP Financial Measures

Adjusted EBITDA isanon-GAAPmeasuredefined as net income (loss) before foreign exchange loss (gain), financial expenses, income tax expense (benefit), depreciation and amortization, stock-based compensationandnon-recurringitemsfor a given period. Adjusted EBITDA is not a measure of our financial performance under U.S. GAAP and should not be considered an alternative to net income or any other performance measures derived in accordance with U.S. GAAP. Accordingly, you should consider Adjusted EBITDA along with other financial performance measures, including net income, and our financial results presented in accordance with U.S. GAAP. Other companies, including companies in our industry, may calculate Adjusted EBITDA differently or not at all, which reduces its usefulness as a comparative measure. We understand that although Adjusted EBITDA is frequently used by securities analysts, lenders and others in their evaluation of companies, Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are: Adjusted EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments; Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; and although depreciation and amortization are non-cashcharges,the assets being depreciated will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.

We believe that Adjusted EBITDA is a useful measure for analyzing the performance of our core business because it facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by changes in foreign exchange rates that impact financial assets and liabilities denominated in currencies other than the U.S. dollar, tax positions (such as the impact on periods or companies of changes in effective tax rates), the age and book depreciation of fixed assets (affecting relative depreciation expense), amortization of intangible assets, stock-based compensation expense (because it isanon-cashexpense)andnon-recurringitemsas explained below.

The following reconciliation of net loss to Adjusted EBITDA for the periods presented:

Venus Concept Inc.Reconciliation of Net losstoNon-GAAPAdjustedEBITDA

Three Months Nine Months Ended September30, Ended September30, 2021 2020 2021 2020 Reconciliation of net (in thousands) (in thousands)loss to Adjusted EBITDANet loss $ (8,838 ) $ (7,321 ) $ (18,031 ) $ (67,789 )Foreign exchange loss 1,645 1,096 2,489 4,209 Interest expense 940 1,750 3,008 6,084 Accretion on long-termdebt and amortization of 60 147 1,038 438 feesIncome tax expense 616 (966 ) 609 (1,010 )(benefit)Depreciation and 1,305 1,181 3,756 3,695 amortizationStock-based compensation 536 547 1,602 1,603 expenseGoodwill impairment ? ? ? 27,450 chargeGain on forgiveness ofgovernment assistance ? ? (2,775 ) ? loansOther adjustments ^(1) 188 2,178 188 7,480 Adjusted EBITDA $ (3,548 ) $ (1,388 ) $ (8,116 ) $ (17,840 )

(1)For the three and nine months ended September 30, 2021, the other adjustments are represented by a loss on the sale of a subsidiary in South Africa ($0.2 and $0.2 million, respectively). For the three and nine months ended September 30, 2020, the other adjustments are mainly represented by severance and retention payments ($nil and $1.4 million, respectively), additional bad debt provision due to COVID-19 ($2.2 million and $5.7 million, respectively) as well as a loss on the sale of a subsidiary in Bulgaria ($nil and $0.4 million, respectively).

Investor Relations Contact:

Westwicke Partners on behalf of Venus Concept:Mike Piccinino, CFAVenusConceptIR@westwicke.com